Kyverna submits full FDA application for stiff person syndrome cell therapy, targeting 2027 launch

Kyverna Therapeutics is working towards a market debut in 2027 for miv-cel, its autologous CAR-T candidate for stiff person syndrome, after sending the final portion of its marketing application to the US Food and Drug Administration. The company, which has no approved product, announced the submission on 12 November 2026 alongside its third-quarter results.

Miv-cel (mivocabtagene autoleucel, also called KYV-101) holds a Regenerative Medicine Advanced Therapy designation, which Kyverna cites in asking for a faster-than-standard review. The filing rests on the registrational KYSA-8 study. The disclosure reviewed by CompePharma does not include efficacy or safety data from that trial, nor any FDA decision on whether to accept the filing or grant the accelerated timetable, so neither is assessed here.

The financial backdrop is that of a pre-revenue company. Kyverna reported cash of $170.6 million and a net loss of $41.9 million for the quarter. It also said it is deprioritising KYV-102, a decision that concentrates its resources on miv-cel, and that enrolment in KYSA-6, its myasthenia gravis study, should finish in mid-2027.

For context, a rolling submission lets a sponsor hand over completed sections of an application as they are ready, and priority review is an FDA designation that aims for a shorter review clock than the standard route. Whether the agency grants it will help determine when, or if, a launch is realistic.